SCHEMBL6353356

SCHEMBL6353356

Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)NC(Cc3ccccc3)C(=O)O)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB1 P05556 1/20 0.49
▸ ITGA4 P13612 1/20 0.49
▸ ITGB3 P05106 1/20 0.48
▸ ITGA2B P08514 1/20 0.48
▸ FPR2 P25090 2/20 0.48
▸ MME P08473 1/20 0.45
▸ ACE P12821 1/20 0.45
▸ ACE2 Q9BYF1 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ CNR1 P21554 4/20 0.45
▸ CNR2 P34972 3/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ HDAC3 O15379 1/20 0.44
▸ HDAC4 P56524 1/20 0.44
▸ HDAC1 Q13547 1/20 0.44
▸ HDAC7 Q8WUI4 1/20 0.44
▸ HDAC2 Q92769 1/20 0.44
▸ HDAC10 Q969S8 1/20 0.44
▸ HDAC11 Q96DB2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6363427 0.89 PPARG (0.47) ACEMEN1KMT2AL3MBTL1PPARA
SCHEMBL6357181 0.87 ALDH1A1 (0.39) ITGB1ITGA4FPR2MEN1KMT2A
SCHEMBL6356970 0.86 P2RY14 (0.56) ACEMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL6356512 0.85 CNR1 (0.41) MEN1KMT2ACNR1CNR2L3MBTL1
SCHEMBL6355470 0.85 MAPK1 (0.45) MEN1KMT2AALDH1A1SMN1; SMN2NPSR1
SCHEMBL6355586 0.83 CNR1 (0.40) MEN1KMT2ACNR1CNR2L3MBTL1
SCHEMBL6355719 0.83 ALDH1A1 (0.40) MEN1KMT2ACNR1CNR2L3MBTL1
SCHEMBL6355164 0.81 ALDH1A1 (0.39) MEN1KMT2ACNR1CNR2L3MBTL1
Efaproxiral SCHEMBL1649963 0.80 PPARA (0.54) MEN1KMT2AL3MBTL1ALDH1A1MAPT
Efaproxiral SCHEMBL3768310 0.79 PPARA (0.52) MEN1KMT2AL3MBTL1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154062-A1 Substituted chiral allosteric hemoglobin modifiers ALLOS THERAPEUTICS, INC. 2005-07-14 — — US disclosed
US-6894185-B2 Substituted chiral allosteric hemoglobin modifiers Allós Therapeutics, Inc. (US) 2005-05-17 — — US disclosed
EP-1206442-A4 SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS UNIV VIRGINIA COMMONWEALTH (US) 2004-12-29 — — EP disclosed
US-20030130523-A1 Substituted chiral allosteric hemoglobin modifiers ABRAHAM DONALD J (US) 2003-07-10 — — US disclosed
US-6486342-B1 Substituted chiral allosteric hemoglobin modifiers VIRGINIA COMMONWEALTH UNIVERSITY 2002-11-26 — — US disclosed
EP-1206442-A1 SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2002-05-22 — — EP disclosed
WO-2001014316-A1 SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2001-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130523-A1 Substituted chiral allosteric hemoglobin modifiers HBZ, HBB, HBG2 ITGB1 2077/4885ITGA4 726/4885ITGB3 1371/4885
US-20050154062-A1 Substituted chiral allosteric hemoglobin modifiers HBZ, HBB, HBG2 ITGB1 2077/4885ITGA4 726/4885ITGB3 1371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback